Search
Talbutal
go.drugbank.com/drugs/DB00306ApprovedIllicitTalbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
Umbilical Cord Blood Hematopoietic Stem Cells
go.drugbank.com/drugs/DB15723InvestigationalFrom the UCB, mononuclear cells are isolated and cultured in medium, expanded, and differentiated into the desired cell type. … Specifically, the proliferation capacity of human umbilical cord blood mononuclear progenitor cells (HUCBC) are much higher than similar cells in bone marrow.
Alcaftadine
go.drugbank.com/drugs/DB06766ApprovedAlcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.
Resatorvid
go.drugbank.com/drugs/DB05943InvestigationalResatorvid is an investigational compound designed for the treatment of severe sepsis.
Bexotegrast
go.drugbank.com/drugs/DB16515InvestigationalIn addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical
Cilansetron
go.drugbank.com/drugs/DB04885ExperimentalCilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Parecoxib
go.drugbank.com/drugs/DB08439ApprovedInvestigationalIt is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. … Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union.
Synonyms: N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamideBioymifi
go.drugbank.com/drugs/DB17493ExperimentalUpon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent. … Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic.